JP2021511352A5 - - Google Patents
Info
- Publication number
- JP2021511352A5 JP2021511352A5 JP2020540571A JP2020540571A JP2021511352A5 JP 2021511352 A5 JP2021511352 A5 JP 2021511352A5 JP 2020540571 A JP2020540571 A JP 2020540571A JP 2020540571 A JP2020540571 A JP 2020540571A JP 2021511352 A5 JP2021511352 A5 JP 2021511352A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- pharmaceutically acceptable
- acceptable salt
- bet inhibitor
- volasertib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18153471.0 | 2018-01-25 | ||
| EP18153471 | 2018-01-25 | ||
| PCT/EP2019/051733 WO2019145410A1 (en) | 2018-01-25 | 2019-01-24 | Combination treatment of acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021511352A JP2021511352A (ja) | 2021-05-06 |
| JP2021511352A5 true JP2021511352A5 (enExample) | 2022-02-01 |
Family
ID=61198661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540571A Pending JP2021511352A (ja) | 2018-01-25 | 2019-01-24 | 急性骨髄性白血病の併用処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210038602A1 (enExample) |
| EP (1) | EP3743067A1 (enExample) |
| JP (1) | JP2021511352A (enExample) |
| CN (1) | CN111629725A (enExample) |
| WO (1) | WO2019145410A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4045687A1 (en) * | 2019-10-16 | 2022-08-24 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy |
| WO2022184664A1 (en) | 2021-03-02 | 2022-09-09 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE50307267D1 (de) | 2003-02-26 | 2007-06-21 | Boehringer Ingelheim Pharma | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| WO2014068402A2 (en) | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| US9422290B2 (en) | 2012-11-13 | 2016-08-23 | Boehringer Ingelheim International Gmbh | Triazolopyridazine |
| US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
| EA201600134A1 (ru) * | 2013-07-26 | 2016-07-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Воласертиб в комбинации с азацитидином для лечения острого миелоидного лейкоза и миелодиспластического синдрома |
| US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428513B2 (en) * | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
| US9428515B2 (en) * | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
| CN107073125A (zh) * | 2014-09-19 | 2017-08-18 | 基因泰克公司 | Cbp/ep300和bet抑制剂用于治疗癌症的用途 |
-
2019
- 2019-01-24 WO PCT/EP2019/051733 patent/WO2019145410A1/en not_active Ceased
- 2019-01-24 JP JP2020540571A patent/JP2021511352A/ja active Pending
- 2019-01-24 CN CN201980009504.0A patent/CN111629725A/zh active Pending
- 2019-01-24 EP EP19700964.0A patent/EP3743067A1/en not_active Withdrawn
- 2019-01-24 US US16/964,023 patent/US20210038602A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133474A5 (enExample) | ||
| JP2023541430A5 (enExample) | ||
| JP2023541432A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| JP2016518387A5 (enExample) | ||
| JP2006504795A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2019515909A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2019517587A5 (enExample) | ||
| JP2020534270A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| JP2023550149A5 (enExample) | ||
| JP2018138596A5 (enExample) | ||
| JP2021530543A5 (enExample) | ||
| JP2022546456A5 (enExample) | ||
| JP2022517902A5 (enExample) | ||
| JP2022511126A5 (enExample) | ||
| JP2021522246A5 (enExample) | ||
| JP2023553253A5 (enExample) | ||
| JP2016505050A5 (enExample) |